A new trading day began on Friday, with VYNE Therapeutics Inc (NASDAQ: VYNE) stock price down -3.33% from the previous day of trading, before settling in for the closing price of $1.2. VYNE’s price has ranged from $0.85 to $4.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 65.87% over the past five years. Meanwhile, its annual earnings per share averaged -10.14%. With a float of $13.63 million, this company’s outstanding shares have now reached $15.96 million.
Let’s look at the performance matrix of the company that is accounted for 13 employees. In terms of profitability, gross margin is 65.95%, operating margin of -7414.88%, and the pretax margin is -6969.42%.
VYNE Therapeutics Inc (VYNE) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of VYNE Therapeutics Inc is 18.19%, while institutional ownership is 36.72%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.71% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
Here are VYNE Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.99, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
VYNE Therapeutics Inc (NASDAQ: VYNE) saw its 5-day average volume 0.49 million, a positive change from its year-to-date volume of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 11.52%.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 15.66%, which indicates a significant increase from 3.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1747 in the past 14 days, which was higher than the 0.1489 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1731, while its 200-day Moving Average is $2.0773. Nevertheless, the first resistance level for the watch stands at $1.2300 in the near term. At $1.3000, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3500. If the price goes on to break the first support level at $1.1100, it is likely to go to the next support level at $1.0600. Assuming the price breaks the second support level, the third support level stands at $0.9900.
VYNE Therapeutics Inc (NASDAQ: VYNE) Key Stats
With a market capitalization of 19.33 million, the company has a total of 15,210K Shares Outstanding. Currently, annual sales are 500 K while annual income is -39,830 K. The company’s previous quarter sales were 200 K while its latest quarter income was -8,610 K.
